Get started

JNJ

JOHNSON & JOHNSON Excellent confirmed sell signalJohnson & Johnson (JNJ) gave us the most optimal buy entry on our last call (April 17, see chart below) and easily hit our 157.50 Target: Having been rejected early in September exactly at the top (Lower Highs trend-line) of the 2-year Channel Down and now establishing price action below its 1D MA50 (blue trend-line), this is a confirmed sell signal and the start of the Channel's 5th Bearish Leg. The RSI Lower Highs are common on all previous Channel tops. Our Target is 141.00, which is on the Internal Lower Lows trend-line (formed by the last 2 Lower Lows) and still above the 1.236 Fibonacci extension. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:JNJShort
by TradingShot
JNJ completing correction wave C NYSE:JNJ JNJ is in multi decade uptrend peaked at 187 – presumably end of major wave 5 and turned into Elliott ABC correction, where major wave (A) length is about 37. Per fibo relation major wave (C) should most probably end at 139.5, while intermediate wave ‘c’ – a unit of the major wave (C) might break the pattern bringing the end of correction to 133 and beyond until possible exhaustion of the major correction at higher fibo multiples. At the same time the stock is trading in a downward channel with a lower bound standing now at 141, as well as built-in triangle pattern identifies target as of 137.5 (not very reliable) Week chart: EMA 50 & 200 confirming death cross – it’s late coz in JNJ case SMA 50/200 confirmed it earlier at around 160 – i.e. the stock is already about to be bottomed. RSI in week chart is not yet oversold, while in day chart RSI is heavily oversold. I would consider weekly and daily RSI to align getting both in oversold territory and open long at somewhere 139-141 with a price target being upper boundary of the current downward channel
NYSE:JNJLong
by mike_volk
How To Pick Top Pharma Stocks like a ProAnalyzing the pharmaceutical industry, whose products play a key role in improving the quality of life of people around the world, is quite challenging sometimes also it requires deep knowledge and a careful approach, as I believe that investors should consider many factors, starting with evaluating the efficacy of the analyzed company's medications, including in relation to its competitors and the "gold standards," and ending with an analysis of its financial indicators In this article you will learn how to pick Top Pharma stocks like a pro trader and which factors you should consider, so buckle up 1/ Recognizing the risks At the very beginning, an investor you must recognize that the pharmaceutical industry is highly competitive, where a company's investment attractiveness depends not only on the rate of expansion of its portfolio of product candidates, revenue growth, margins, the amount of total debt and cash on the balance sheet but is also heavily influenced by the expiration of patents on medications and vaccines. Moreover, in recent months, the healthcare sector has increasingly felt the impact of the upcoming 2024 US presidential elections, as some politicians are aiming to further tighten regulation of drug prices despite the existing Inflation Reduction Act. 2/ Leveraging data to your advantage The second step use data wisely, you should check all kinda data including stock screener, transcripts of earnings calls, financial results for the last quarters, analyst expectations, options data... The goal is to filter companies in poor financial condition, as well as those that trade at a significant premium to the sector and/or competitors I would also like to point out that in the current market environment, with Fed interest rates remaining at multi year highs, I do not recommend investing in companies with market caps below $500 million, as they typically have limited cash reserves and weaker institutional backing Also, I'd recommend investors read 10-Ks and 10-Qs, especially the section related to debt and sources of financing of the company's operations, to reduce the likelihood of an "unexpected" drop in the share price. A striking example is Invitae Corporation aka NVTAQ which declared bankruptcy in mid February 2024! Was there a prerequisite for this? The answer is yes since the company continued to generate negative cash flow and also had convertible senior notes maturing in 2028. Convertible notes can involve significant financial risks if the company cannot effectively use the cash to grow the business and break even. In this case, management will not be able to pay off the bonds with cash reserves and will have to resort to significant dilution of investors. In my opinion, Pacific Biosciences of California, Inc. NASDAQ:PACB may face this problem because it has convertible senior notes maturing in 2028 and 2030. Factors that concern me include the company's declining revenue and total cash and short-term investments in recent quarters, while its operating expenses remain extremely high at around $80 million per quarter. Let's return to the second step in my approach to selecting the most promising assets in the healthcare sector. When selecting companies with market caps between $4 billion and $40 billion, I use more parameters since most of them already have FDA approved drugs and/or vaccines. As a result, it is also necessary to consider the rate of growth of operating income, net debt/EBITDA ratio, and how management copes with increased marketing and production costs. Finally, let's move on to the last basket, which contains pharmaceutical companies with market capitalizations exceeding $40 billion. I think, this group is best suited for more conservative investors looking for assets offering attractive dividend yields and growing net income, supported by a rich portfolio of FDA approved and experimental drugs. So, from Big Pharma, I like Pfizer Inc NYSE:PFE , AbbVie Inc NYSE:ABBV , Merck & Co NYSE:MRK and AstraZeneca PLC NASDAQ:AZN . I also want to include Novartis AG NYSE:NVS and Roche Holding AG OTC:RHHBY in this group sometimes investors need to make exceptions, namely if one larger company buys out a smaller player and/or when a major partnership agreement is concluded, as was the case between Merck and Daiichi Sankyo Company, Limited OTC:DSKYF in 2023. Also, in the event of a major acquisition or merger, the company's debt may temporarily increase sharply. If its management has previously implemented effective R&D and financial policies, the "net debt/EBITDA ratio" A remarkable example of a company falling into the "value trap" is Takeda Pharmaceutical Company Limited NYSE:TAK , which overpaid for Shire. This deal did not significantly strengthen or rejuvenate the Japanese company's portfolio of drugs. As a result, it had to sell off billions of dollars in assets to pay off its debt partially. However, despite all the efforts of Takeda's management, its net debt/EBITDA ratio, although it fell below 5x, remains high, namely about 4.7x at the end of March 2024. 3/ Identifying promising therapeutic areas In general, the more prevalent a disease is, the larger the total addressable market for a drug and, as a result, the higher the chances that it will become a commercially successful product. Global spending on cancer medications will reach $377 billion by 2027, followed by immunology, and diabetes will come in third with an estimated spending of about $169 billion What challenges arise when choosing pharmaceutical companies? you should also keep in mind that the larger the market, the higher the competition between medicines, as companies strive to grab as big a piece of the pie as possible. As a result, for drug sales to take off, they need to have significant competitive advantages over the "gold standard." These competitive advantages may include greater efficacy in treating a particular disease, less frequent administration, a more favorable safety profile, and a more convenient route of administration. So, in recent years, competition in the global spinal muscular atrophy treatment market has intensified. Spinal muscular atrophy is a genetic condition. Currently, three drugs have been approved to combat the disorder, including Biogen Inc.'s (BIIB) Spinraza, Roche/PTC Therapeutics, Inc.'s (PTCT) Evrysdi, and Novartis AG's (NVS) gene therapy Zolgensma. All three products have similar efficacy, but Evrysdi has a more favorable safety profile and is the more convenient route of administration, namely the oral route, which is reflected in its sales growth rate from year to year. The second pitfall is the company's pipeline of experimental drugs. I believe that financial market participants opening an investor presentation that presents a company's pipeline, especially if its market cap is below $5 billion, should also pay close attention to what stage of clinical trial activity its experimental drugs are in. if a pharmaceutical company has most of its product candidates in the early stages of development, this represents a significant risk because, in this case, institutional and retail investors are often overly optimistic about the prospects for the drugs' mechanisms of action and/or clinical data obtained in a small group of patients. Simultaneously, as is often the case, the higher the optimism, the less favorable the risk/reward profile. In most cases, the larger and more diverse the patient population, the weaker the efficacy of a drug relative to what was seen in Phase 1/2 clinical trials. This ultimately leads to a downward valuation of its likelihood of approval and casts doubt on its ability to take significant market share from approved medications. This may subsequently reduce the company's investment attractiveness, making it more difficult to attract financing for its operating activities. As a result, I recommend excluding any company that, instead of focusing its financial resources on the most promising product candidates, conducts multiple early-stage clinical trials to evaluate the efficacy of its experimental drugs. In my experience, the most successful pharmaceutical companies focus their efforts on bringing up to three product candidates to market and then reinvesting the revenue from their commercialization into developing the rest of the pipeline. The table below highlights the following parameters that I use to screen out the least promising companies. A third factor that investors, especially those new to the investment world, should consider is that large pharmaceutical companies are leaders in certain therapeutic areas, with a rich portfolio of patents covering various mechanisms of action and delivery methods of drugs, making it more difficult and more prolonged for smaller players to find product candidates that could potentially have the competitive advantages. So, Novo Nordisk A/S NYSE:NVO and Eli Lilly and Company NYSE:LLY have long been leaders in the global diabetes and weight loss drugs markets, and only very recently, they may be joined by Amgen Inc. NASDAQ:AMGN , Roche Holding, and several other companies 4/ Assessing a company's drug portfolio in comparison to competitors Evaluating the effectiveness, safety profile, and mechanism of action of a medication, as well as comparing clinical data with its competitors, takes a lot of time and effort. I provided examples of drugs and the most promising mechanisms of action in the obesity treatment market. Their manufacturers are Eli Lilly, Novo Nordisk, Roche Holding, Viking Therapeutics, Inc, Amgen, Pfizer, Altimmune, Inc, OPKO Health, Inc, Boehringer Ingelheim, and Zealand Pharma A/S 5/ When market exclusivity for a company's key medications ends Every financial market participant who is considering investing in pharmaceutical companies should consider the expiration time of key patents of medicines. Marketing exclusivity represents protection against the entry of a generic version and/or biosimilar of a branded drug into the market, thereby allowing the company to recoup the resources spent on its development and, in the event of its commercial success, also reinvest the money received to accelerate the development of the remaining product candidates. Where can you find information about patent expiration dates? All the necessary information is either in 20-Fs/10-Ks or on the FDA website, namely in the "Orange Book" section. let's take Eli Lilly as an example. Open the latest 10-K. Then, the CTRL + F combination opens the ability to find specific words in the document. I usually enter "Expiry Date" or "compound patent" to find the patent section.nvestors can also find information about patents on the FDA website. As an example, I enter "Mounjaro" in the top line, and a list of patents opens that protect Eli Lilly's blockbuster from the introduction of its generic versions onto the market.hen, clicking on "Appl. No." will open information about the submission date of the patent and when it will expire. 6/ Evaluating the impact of insider share transactions The next step in selecting the most interesting assets in the healthcare sector is to analyze Form-4s. The CEO, CFO, and other key members of the company's management buy or sell shares from time to time.I am only interested in analyzing purchases since, most often, sales by management are option exercises carried out to pay taxes. When management starts making large outright purchases of a company's shares, it can signal that it believes in its long-term growth potential.if more than two top managers buy a large block of shares within two weeks of each other, it significantly increases the likelihood of the company's stock price rising in the next two months from the moment of their transactions But as with everything, there are exceptions, such as in the case of OPKO Health, which is developing a long-acting oxyntomodulin analog for the treatment of obesity together with LeaderMed Group.Over the past 12 months, OPKO's management, especially CEO Phillip Frost, has purchased over 12 million shares. However, despite this, its stock price has fallen by 27% over the same period. I believe that the key reasons for the divergence between these two facts are investors' lack of confidence in Phillip Frost's ability to make the company profitable again, as well as its low cash reserves. Therefore, companies like OPKO Health have already been eliminated at the second step of selection using Seeking Alpha's screener. 7/ CEO Performance in Business Development The CEO plays a crucial role in the success of a pharmaceutical company since the pharmaceutical industry is highly dynamic, and the competition between Big Pharma is especially high, I advise readers to pay attention to the track record of the CEO, especially how he copes with force majeure situations, as well as how effective the R&D policy is carried out under his leadership. 8/ Identifying Entry and Exit Points for Long-Term Investments The eighth step is in addition to the information that was obtained in the previous steps, as well as the analysis of financial risks and various financial metrics of the company, including its net debt, maturity dates of bonds, historical revenue growth rates, EBIT, gross margin, I build a DCF model with the ultimate goal of determining the price target. it is necessary to conduct a technical analysis of them, as well as the main ETFs that include them. In my opinion, the key ETFs are the SPDR® S&P Biotech ETF AMEX:XBI , Fidelity Blue Chip Growth ETF AMEX:FBCG , iShares Biotechnology ETF NASDAQ:IBB , and VanEck Pharmaceutical ETF $PPH. The purpose of technical analysis is to determine the stop-loss level and entry points at which the risk/reward profile is most favorable. taking profit is not that easy cuz you must master your emotions and greed which damn hard 9/ Creating a Watchlist Based on Risk/Reward Ratio The purpose of which is to create a watchlist of the companies I have selected based on the previous steps. I make several lists of companies based on their market caps and also rank them according to risk/reward profile, that is, in the first place is the stock that I think has minimal risks and at the same time can bring the greatest potential profit. I also advise creating small notes on each company, which can include information about risks, support/resistance zones, dates of publication of clinical data, and any thoughts you have that will make your decision more conscious when opening a position “What’s your secret sauce for choosing pharma stocks?”
NYSE:NVOEducation
by moonypto
Johnson & Johnson (JNJ) - Approaching the Reversal ZoneIn April, we anticipated a pullback for JNJ, and since then, the stock has dropped approximately 7%, aligning with our expectations. The current trend suggests further downward movement, reinforcing our previous analysis. We are focusing on the support zone ranging from $134 to $116, with a potential lower bound at $109, the Corona-Low. The ongoing pullback could represent the completion of Wave (4) within this target zone, aligning with multiple levels. We are going to be monitoring this for signs of a reversal within this zone. This zone will be crucial to confirm the next possible upward movement.
NYSE:JNJLong
by freeguy_by_wmc
1
J&J Entangled in Talc-Related Lawsuits and Bankruptcy AllegationCore Issues: * J&J faces numerous lawsuits alleging its talc products contain asbestos and cause cancer. * The company's utilization of a "Texas two-step" bankruptcy strategy to shield assets from litigation has drawn accusations of fraud. Recent Developments: * Cancer victims filed a class action lawsuit on May 22nd, 2024, alleging J&J's fraudulent use of bankruptcy and asset transfers to avoid compensation. * J&J maintains the safety of its talc and claims the lawsuit disrupts their proposed settlement plan. Broader Implications: * This legal battle raises concerns about potential abuses of bankruptcy laws by corporations seeking to evade product liability. * The case has significant financial ramifications for J&J, with analysts citing negative impacts on stock valuation. Conclusion: * The outcome of these lawsuits will determine compensation for victims, J&J's future financial liabilities, and potentially set precedents for corporate responses to mass tort claims. * Upcoming developments, such as the claimant's vote on the settlement and the court's response to the latest bankruptcy filing, will be crucial in resolving this protracted dispute.
NYSE:JNJShort
by signalmastermind
Johnson & Johnson's Q1 Triumph: Surpassing ExpectationsJohnson & Johnson (NYSE: NYSE:JNJ ) has kicked off 2024 with a resounding victory, showcasing robust first-quarter earnings that outpaced Wall Street estimates and signaling a promising trajectory for the rest of the year. The pharmaceutical giant reported an impressive adjusted EPS of $2.71, marking a remarkable 12.4% surge compared to the previous year. This stellar performance surpassed analysts' projections of $2.64, underscoring the company's resilience and strategic prowess. In terms of revenue, Johnson & Johnson ( NYSE:JNJ ) posted sales of $21.38 billion, reflecting a steady 2.3% increase year over year. While this figure nearly mirrored market expectations, the operational growth of 3.9% and adjusted operational growth of 4.0% underscored the company's underlying strength and adaptability in navigating market dynamics. One of the standout performers in Johnson & Johnson's portfolio was its Innovative Medicine segment, which witnessed robust operational sales growth of 8.3% to reach $13.6 billion. Notably, sales of key drugs such as Stelara and Darzalex demonstrated resilience, with the latter experiencing a notable 19% surge in revenue. Moreover, the company's medical devices business proved to be a significant driver of growth, generating sales of $7.82 billion during the quarter, marking a commendable 4.5% year-over-year increase. This uptick was fueled by strong performances in electrophysiology products and cardiovascular solutions, showcasing Johnson & Johnson's ( NYSE:JNJ ) diverse revenue streams and market leadership in healthcare innovation. In a move sure to delight investors, Johnson & Johnson ( NYSE:JNJ ) announced a 4.2% increase in its quarterly dividend, a testament to its commitment to delivering value to shareholders amidst a challenging economic landscape. Looking ahead, Johnson & Johnson ( NYSE:JNJ ) raised its fiscal year 2024 guidance, projecting operational sales in the range of $88.7 billion to $89.1 billion and adjusted EPS between $10.57 and $10.72. This optimistic outlook, coupled with the company's track record of delivering on its promises, instills confidence in its ability to navigate future opportunities and challenges. Despite a slight dip in premarket trading following the earnings release, Johnson & Johnson's ( NYSE:JNJ ) strong performance in Q1 sets a solid foundation for continued success, reaffirming its position as a leader in the healthcare industry and a reliable investment choice for shareholders worldwide.
NYSE:JNJ
by DEXWireNews
JOHNSON & JOHNSON Time to start buying.Johnson & Johnson (JNJ) quickly hit the $147.00 Target that we set on our very recent sell call (April 03, see chart below) and is now approaching the bottom of the massive 2-year Channel Down: Even though based on the very reliable and consistent Sine Waves, the bottom might be a process that can take up to 2-months, the stock is low enough for medium-term investors to start considering adding buys. On top of that, the 1D RSI is highly oversold below 20.00, the lowest it has been in more than 4 years (since February 28 2020)! As a result and since the Bearish Legs of this Channel Down have ranged within -14.78% and -17.58%, we are turning bullish on this stock, targeting $157.50 (minimum +13.00% rise as with January 22 2024 High). ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:JNJLong
by TradingShot
JNJ has bottomed and can rise by +50%Johnson & Johnson gives a very clear idea of its trend on the 1M timeframe. The price may be under the 1D MA50 but has reached the bottom of the multi year Channel Up that started at the bottom of the 2008-2009 crisis. Being neutral on the 1M technical outlook (RSI = 45.714, MACD = -1.180, ADX = 20.525) has historically been one of the best buy opportunities, in fact the stock has grown by at least +53.04% three time during that time span. We shouldn't also ignore the fact that the 1M MA100 is still holding and has been doing so since June 2012. We are aiming long term for at least +53.04% again (TP = 220.00). ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:JNJLong
by InvestingScope
JOHNSON & JOHNSON More pain along the way. SELL.Johnson & Johnson (JNJ) got rejected on its 1D MA200 (orange trend-line) - 1D MA50 (blue trend-line) Resistance Zone. It has been practically trading sideways since the start of the year and based on the Sine Waves, that priced the new Top (Lower Highs trend-line) of the 2-year Channel Down pattern. The expected completion of a Bearish Cross this week on the 1W RSI, will confirm the Sell Signal, as all 3 previous Bearish Cross sequences were forme just after a Top. Though their declines ranged from -17.58% to -14.78%, we will use the October 10 2022 Low as an example and target the 0.9 Fibonacci retracement level at 147.00 as since the Bullish Leg was limited, we expect an equally less aggressive Bearish Leg towards the bottom of the Sine Waves. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:JNJShort
by TradingShot
JNJ is expected to report earnings to fall -14.29% to $2.28 per The last earnings report on September 30 showed earnings per share of $2.66, beating the estimate of $2.51. P/B Ratio (5.353) is normal, around the industry mean (5.180). P/E Ratio (29.715) is within average values for comparable stocks, (34.823). Projected Growth (PEG Ratio) (1.572) is also within normal values, averaging (3.115). Dividend Yield (0.030) settles around the average of (0.029) among similar stocks. P/S Ratio (4.199) is also within normal values, averaging (3.589). With 6.92M shares outstanding, the current market capitalization sits at 381.26B.
J
by Serhii_Bond
The Healthcare Sector Index $XLV - Worth Watching SPDR Select Sector Fund – Healthcare Index AMEX:XLV The chart speaks for itself, we have our breakout levels and our break down levels. We enter on a breakout and set a stop 5% under that support and we exit and or short if we fall under the two underside support levels. Below I outline some reasons why the healthcare sector is worth paying attention too. The healthcare industry is worth $808 billion in the United States as of 2021. 65% of the industry’s revenue comes from patient care. The global healthcare industry is worth $12 trillion. In the U.S National health expenditures are projected to grow 5.4 percent, on average, over the course of 2023–31 and to account for roughly 20 percent of the economy by the end of that period. The insured share of the population is anticipated to exceed 92 percent through 2023 (figures pending), in part as a result of record-high Medicaid enrolment, and then decline toward 90 percent as coverage requirements related to the COVID-19 public health emergency expire. The growth of the health-care sector is evident in employment data as well. In 1990, about 8 million Americans worked in health care; that figure has since doubled to 16 million. That’s the largest single employment segment in our economy. In addition to the above, the west in general is an aging populace that is living longer. We will need these services more than we need staples during a recession. I believe this index can help us gauge the healthcare sector and what direction it will go next. We can watch the levels outlines and make a play if we wish. We have a hard upper boundary and lower boundary on a parallel channel on the chart. You know what to do when we breach any of these levels. Outlined on the chart XLV fund provides exposure to companies in pharmaceuticals, health care equipment and supplies, health care providers and services, biotechnology, life sciences tools and services, and health care technology industries. XLV is the oldest in the segment, as such it is used widely for strategic or tactical positions. Since XLV is both cap weighted and fishes only from the S&P 500, it tilts heavily toward mega-caps. For focused exposure to leading health care names, XLV is tough to beat. Top Five Holdings UnitedHealth Group Inc NYSE:UNH 9.63% Eli Lilly and Co NYSE:LLY 9.19% Johnson & Johnson NYSE:JNJ 7.46% Merck & Co NYSE:MRK 5.46% AbbVie Inc 5.41% Stay Healthy and Nimble Folks PUKA
AMEX:XLV
by PukaCharts
JNJ - Macro View 🌐Hello TradingView Family / Fellow Traders. This is Richard, also known as theSignalyst. 📈 JNJ has exhibited an overall bullish trend, trading within the ascending wedge pattern outlined in blue. It is presently nearing the lower boundary/blue trendline. At present, JNJ is undergoing a correction phase and is trading within the descending red channel. It is currently approaching the lower limit and a highlighted demand zone in green. 🏹 Thus, the highlighted purple circle is a strong area to look for buy setups as it is the intersection of the green demand and lower blue and red trendlines acting as a non-horizontal support. 📚 As per my trading style: As JNJ approaches the lower purple circle zone, I will be looking for bullish reversal setups (like a double bottom pattern, trendline break , and so on...) 📚 Always follow your trading plan regarding entry, risk management, and trade management. Good luck! All Strategies Are Good; If Managed Properly! ~Rich
NYSE:JNJ
by TheSignalyst
1
JOHNSON & JOHNSON Double buy entry.JNJ touched Support (1) at 153.20, a level holding since June 1st. Along with Support (2) at 150.10 are the major buy levels for the long term. The medium term Resistance is the MA200 (1d). Trading Plan: 1. Buy on the current market price. 2. If Support (1) breaks, buy on Support (2). Targets: 1. 162.00 (expected contact point with the MA200 (1d)). 2. 161.00 (expected contact point with the MA200 (1d)). Tips: 1. The RSI (1d) shows that the stock price in the past 12 months bottoms a little after the RSI forms a Double Bottom. It makes a slightly lower low. Be on the look out for one. Please like, follow and comment!!
NYSE:JNJLong
by TradingBrokersView
How To Analyze Any Chart 📚📹Hello TradingView Family / Fellow Traders. This is Richard, also known as theSignalyst. Today we are going to go over a practical example on #JNJ , but you can apply the same logic / strategy on any instrument. Feel free to ask questions or request any instrument for the next episode. 📚 Always remember to follow your trading plan when it comes to entry, risk management, and trade management. Good luck! Remember, all strategies are good if managed properly! ~Rich
NYSE:JNJ
by TheSignalyst
55
KVUE Split-off: A Response to JNJ's Cancer-Related Products?It is plausible to consider that Johnson & Johnson's decision to spin off Kenvue might be linked to an effort to mitigate potential legal liabilities stemming from its talc-based products, which have been implicated in cases of cancer in the US and Canada. This strategic maneuver could potentially offer a layer of legal protection. Shareholders are expected to transition from holding Johnson & Johnson shares to Kenvue shares in the upcoming week. A similar approach was attempted by MMM, although it did not yield successful results, causing a downward trajectory in its stock performance over the past two years. From my perspective, the true rationale behind the division appears to be related to the numerous instances of individuals developing cancer due to Johnson & Johnson's talc-based products. A recent legal ruling mandated Johnson & Johnson to pay $18.8 million to a California resident who claimed to have contracted cancer from using its baby powder. This decision represents a setback for the company as it seeks resolution for thousands of comparable cases related to its talc-based products within a US bankruptcy court. Johnson & Johnson recently disclosed detailed information regarding the much-anticipated division of its consumer healthcare venture, Kenvue. This move involves a separation of at least 80.1% of Kenvue shares, facilitated through an exchange offer presented to investors. Within this arrangement, shareholders have the flexibility to trade all, a portion, or none of their Johnson & Johnson shares for Kenvue stock. The company is extending the choice to its investors, allowing them to opt for an exchange of shares for Kenvue stock. To incentivize this exchange, a 7% discount is being offered on the shares. However, there is an upper threshold of 8.0549 Kenvue shares for each Johnson & Johnson share. If this ceiling is not applicable, shareholders will receive approximately $107.53 worth of Kenvue shares for every $100 worth of Johnson & Johnson stock they intend to exchange. The execution of this exchange offer is anticipated to conclude by mid-August. Notably, this exchange program is voluntary and carries tax-free advantages. Kenvue has outlined plans to distribute a portion of its available funds to shareholders through dividend payments. The company has recently initiated a quarterly dividend of $0.20 per share (equivalent to $0.80 annually), with the first payout scheduled for early September. This dividend framework translates to a dividend yield of 3.3% based on the prevailing stock price of approximately $24 per share. This yield marginally exceeds Johnson & Johnson's existing dividend yield of 2.8%. It is likely that a significant portion of individuals holding Johnson & Johnson stock will opt to exchange their shares for Kenvue. Based on this assessment, I anticipate that Kenvue's stock could potentially reach $30 in the near future. Looking forward to read your opinion about it!
NYSE:KVUELong
by TopgOptions
JOHNSON & JOHNSON Buy opportunity.Johnson & Johnson is trading inside an Ascending Triangle pattern with the 1D technicals neutral (RSI = 49.652, MACD = -0.360, ADX = 36.021). The 1D MACD is close to making a Buy Cross so today's cross over the 1D MA50 is a first buy signal, that targets the 1D MA200 (TP = 165.00). If the price crosses over the R1 (167.25) we will buy again targeting the R2 (TP = 181.15), which is exactly on the 2.0 Fibonacci extension level. ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:JNJLong
by InvestingScope
1
Profits Over Patients: The Morally Complex Realm of Big PharmaThis strategy dissects the dual nature of big pharmaceutical firms like Johnson & Johnson, Pfizer, Moderna, and Merck & Co viewed through base Fibonacci Extension Clustering. Despite big pharma's significant contributions to healthcare, these firms have benefited from questionable practices, including price manipulation and exploiting addictions . Price manipulation is a notorious strategy where companies arbitrarily hike drug prices, often without any significant improvements in their efficacy. "Big Pharma" has faced backlash for allegedly contributing to the opioid crisis . By aggressively marketing highly addictive pain medications , they may have exacerbated a public health catastrophe, leading to thousands of deaths annually. Such practices illuminate the immoral landscape of the pharmaceutical industry. While these firms play a vital role in global healthcare, their business tactics often prioritize profits over patients, demanding a closer scrutiny of this sector's ethics. 1. Johnson & Johnson (JNJ): Around $440 billion 2. Pfizer Inc. (PFE): Around $240 billion 3. Moderna Inc. (MRNA): Around $110 billion 4. Merck & Co., Inc. (MRK): Around $200 billion TOTAL = 1 Trillion
NASDAQ:MRNA
by MichaelBsul